These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 25918937)

  • 1. Insights on Structural Characteristics and Ligand Binding Mechanisms of CDK2.
    Li Y; Zhang J; Gao W; Zhang L; Pan Y; Zhang S; Wang Y
    Int J Mol Sci; 2015 Apr; 16(5):9314-40. PubMed ID: 25918937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclin B and cyclin A confer different substrate recognition properties on CDK2.
    Brown NR; Lowe ED; Petri E; Skamnaki V; Antrobus R; Johnson LN
    Cell Cycle; 2007 Jun; 6(11):1350-9. PubMed ID: 17495531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of a potential allosteric ligand binding site in CDK2.
    Betzi S; Alam R; Martin M; Lubbers DJ; Han H; Jakkaraj SR; Georg GI; Schönbrunn E
    ACS Chem Biol; 2011 May; 6(5):492-501. PubMed ID: 21291269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural prediction of the interaction of the tumor suppressor p27
    Li J; Vervoorts J; Carloni P; Rossetti G; Lüscher B
    BMC Bioinformatics; 2017 Jan; 18(1):15. PubMed ID: 28056778
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Type II Inhibitors Targeting CDK2.
    Alexander LT; Möbitz H; Drueckes P; Savitsky P; Fedorov O; Elkins JM; Deane CM; Cowan-Jacob SW; Knapp S
    ACS Chem Biol; 2015 Sep; 10(9):2116-25. PubMed ID: 26158339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-based approaches to improve selectivity: CDK2-GSK3beta binding site analysis.
    Vulpetti A; Crivori P; Cameron A; Bertrand J; Brasca MG; D'Alessio R; Pevarello P
    J Chem Inf Model; 2005; 45(5):1282-90. PubMed ID: 16180905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Specific Conformational Dynamics and Expansion Underpin a Multi-Step Mechanism for Specific Binding of p27 with Cdk2/Cyclin A.
    Tsytlonok M; Hemmen K; Hamilton G; Kolimi N; Felekyan S; Seidel CAM; Tompa P; Sanabria H
    J Mol Biol; 2020 Apr; 432(9):2998-3017. PubMed ID: 32088186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular Dynamics Simulations and Classical Multidimensional Scaling Unveil New Metastable States in the Conformational Landscape of CDK2.
    Pisani P; Caporuscio F; Carlino L; Rastelli G
    PLoS One; 2016; 11(4):e0154066. PubMed ID: 27100206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autocatalytic phosphorylation of CDK2 at the activating Thr160.
    Abbas T; Jha S; Sherman NE; Dutta A
    Cell Cycle; 2007 Apr; 6(7):843-52. PubMed ID: 17361108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular dynamics and QM/MM-based 3D interaction analyses of cyclin-E inhibitors.
    Pasha FA; Neaz MM
    J Mol Model; 2013 Feb; 19(2):879-91. PubMed ID: 23086460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel binding pocket of cyclin-dependent kinase 2.
    Chen H; Van Duyne R; Zhang N; Kashanchi F; Zeng C
    Proteins; 2009 Jan; 74(1):122-32. PubMed ID: 18615713
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of phosphorylated Thr160 for the activation of the CDK2/Cyclin A complex.
    De Vivo M; Cavalli A; Bottegoni G; Carloni P; Recanatini M
    Proteins; 2006 Jan; 62(1):89-98. PubMed ID: 16292742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An analysis of the binding modes of ATP-competitive CDK2 inhibitors as revealed by X-ray structures of protein-inhibitor complexes.
    Vulpetti A; Pevarello P
    Curr Med Chem Anticancer Agents; 2005 Sep; 5(5):561-73. PubMed ID: 16178778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors.
    Nandha Premnath P; Craig S; McInnes C
    J Vis Exp; 2015 Oct; (105):e52441. PubMed ID: 26554946
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The C-terminal regulatory domain of p53 contains a functional docking site for cyclin A.
    Luciani MG; Hutchins JR; Zheleva D; Hupp TR
    J Mol Biol; 2000 Jul; 300(3):503-18. PubMed ID: 10884347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of an hexapeptide that binds to a surface pocket in cyclin A and inhibits the catalytic activity of the complex cyclin-dependent kinase 2-cyclin A.
    Canela N; Orzáez M; Fucho R; Mateo F; Gutierrez R; Pineda-Lucena A; Bachs O; Pérez-Payá E
    J Biol Chem; 2006 Nov; 281(47):35942-53. PubMed ID: 17001081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A flexible-protein molecular docking study of the binding of ruthenium complex compounds to PIM1, GSK-3β, and CDK2/Cyclin A protein kinases.
    Liu Y; Agrawal NJ; Radhakrishnan R
    J Mol Model; 2013 Jan; 19(1):371-82. PubMed ID: 22926267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel approach to the discovery of small-molecule ligands of CDK2.
    Martin MP; Alam R; Betzi S; Ingles DJ; Zhu JY; Schönbrunn E
    Chembiochem; 2012 Sep; 13(14):2128-36. PubMed ID: 22893598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CDK1 structures reveal conserved and unique features of the essential cell cycle CDK.
    Brown NR; Korolchuk S; Martin MP; Stanley WA; Moukhametzianov R; Noble MEM; Endicott JA
    Nat Commun; 2015 Apr; 6():6769. PubMed ID: 25864384
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-based discovery of the first allosteric inhibitors of cyclin-dependent kinase 2.
    Rastelli G; Anighoro A; Chripkova M; Carrassa L; Broggini M
    Cell Cycle; 2014; 13(14):2296-305. PubMed ID: 24911186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.